Onchocerciasis is a debilitating parasitic disease caused by the filarial worm Onchocerca volvulus. Similar to other helminth parasites, O. volvulus is capable of evading the host's immune responses by a variety of defense mechanisms, including the detoxification activities of the glutathione S-transferases (GSTs). Additionally, in response to drug treatment, helminth GSTs are highly up-regulated, making them tempting targets both for chemotherapy and for vaccine development. We analyzed the three-dimensional x-ray structure of the major cytosolic GST from O. volvulus (Ov-GST2) in complex with its natural substrate glutathione and its competitive inhibitor S-hexylglutathione at 1.5 and 1.8 Å resolution, respectively. From the perspective of the biochemical classification, the Ov-GST2 seems to be related to -class GSTs. However, in comparison to other -class GSTs, in particular to the host's counterpart, the Ov-GST2 reveals significant and unusual differences in the sequence and overall structure. Major differences can be found in helix ␣-2, an important region for substrate recognition. Moreover, the binding site for the electrophilic co-substrate is spatially increased and more solvent-accessible. These structural alterations are responsible for different substrate specificities and will form the basis of parasite-specific structure-based drug design investigations.Onchocerciasis is a parasitic disease caused by the filarial worm Onchocerca volvulus. It is often called river blindness because of its most extreme manifestation and because the blackflies that transmit the disease breed in fast flowing waters. It is the world's second leading infectious cause of blindness. About 18 million people are infected with O. volvulus in Africa, the Arabian Peninsula, and Central and South America. Moreover, roughly 50 million individuals are at risk of acquiring the parasite. Onchocerciasis causes chronic suffering and severe disability. Furthermore, it significantly impedes the socio-economic development in affected communities (www.who.int/tdr/index.html).Chemotherapeutic approaches to control parasite transmission and to treat onchocerciasis rely on drugs that only kill microfilariae and infectious larvae but not the adult parasites. So far this necessitates the continuous use of these microfilaricides until the adult worms die. Therefore, the development of drugs that also effectively kill the adult worms would greatly support the control and treatment of O. volvulus infections (1). Furthermore, the potential development of drug-resistant strains of the nematode also demands the identification of alternative drug candidates to control the disease (2).O. volvulus, similar to other parasitic organisms, is capable of surviving in an immunologically competent host by employing a variety of immune evasion strategies and defense mechanisms, including the detoxification and the repair mechanisms of glutathione S-transferases (GSTs 1 ; EC 2.5.1.18). GSTs are an ancient and diverse superfamily of multifunctional proteins repre...